1. Thailand Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Inter Pharma Public Company Limited

Inter Pharma Public Company Limited

4.92
THB
-0.02
(-0.40%)
0.26EPS
19.57P/E
2.70BMarket Cap
Nov 17Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.52
0.67
1.04
0.94
1.91
2.86
2.94
3.13
3.62
3.71
Basic EPS, GAAP
0.03
0.06
0.12
0.11
0.22
0.22
0.08
0.06
0.2
0.23
Free Cash Flow per Basic Share
0.02
-0.03
0.01
-0.05
-0.59
0.18
-0.04
-0.14
0.27
0.2
Dividend per Share
0.08
0.06
0.03
0.08
0.01
- -
0.11
0.02
- -
0.07
Book Value per Share
0.16
0.21
0.97
1
1.57
3.18
3.16
3.2
3.4
3.44
Tangible Book Value per Share
0.16
0.21
0.96
0.85
1.41
2.12
2.05
1.91
2.11
2.16
Basic Weighted Avg Shares
471
471
356
470
475
532
605
605
605
605
Sales/Revenue/Turnover
247
317
371
442
909
1,523
1,781
1,897
2,193
2,243
Operating Margin (%)
11.58
12.93
16.63
17.4
16.04
11.21
6.14
3.91
8.75
9.66
Depreciation Expense
1
2
2
6
27
66
98
113
117
121
Net Income, GAAP
16
30
43
53
105
119
51
37
122
138
Effective Tax Rate (%)
33.27
27.84
22.68
21.67
19.75
13.23
27.61
30.61
20.5
21.48
Profit Margin (%)
6.36
9.37
11.71
11.88
11.58
7.8
2.85
1.93
5.58
6.15
Working Capital
65
89
449
257
331
1,017
724
456
468
498
LT Debt
- -
- -
- -
93
189
387
260
233
186
168
Total Equity
79
107
466
486
784
2,116
2,118
2,158
2,299
2,333
Return on Invested Capital (%)
- -
29.59
15.95
11.07
13.33
7.79
3.07
2.05
5.85
6.41
Return on Capital (%)
- -
30.73
13.57
8.64
12.18
6.89
2.37
1.99
4.73
5
Return on Common Equity (%)
- -
34.15
15.63
11.35
17.09
8.85
2.65
1.9
6.13
6.77

Capital Structure

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
215
199
195
LT Borrowings
124
124
118
LT Finance Leases
62
54
50
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
605
605
605
Market Capitalization
2,785
2,446
2,700

Working Capital

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,106
1,161
1,129
Cash, Cash Equivalents & STI
282
305
243
Accounts Receivable, Net
365
344
339
Inventories
350
385
416
Total Current Liabilities
638
645
631
Payables & Accruals
398
416
408
ST Debt
215
199
195
Deferred Revenue
5
9
7

Growth Rates

THB

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
47.94%
6.54%
Free Cash Flow
- -
162.62%
-296.36%
Net Income, GAAP
- -
52.41%
233.93%
Sales/Revenue/Turnover
- -
42.45%
15.61%
Total Cash Common Dividend
- -
- -
-100%

Quarterly Revenue

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
484
445
436
532
1,897
2025
531
535
556
572
2,193
2026
560
555
- -
- -
- -

Quarterly Earnings Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.01
0.01
0.02
0.06
2025
0.04
0.05
0.07
0.04
0.2
2026
0.06
0.05
- -
- -
- -

Quarterly Dividends Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
- -
- -
0.02
2025
- -
- -
- -
- -
- -
2026
- -
0.07
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Trinnawat Thanitnithiphan
Full Time Employees
64
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 140/9 ITF Tower Bangkok BM Thailand 10500
IPO Date
Nov 5, 2019
Website
interpharma.co.th
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Inter Pharma Public Company Limited manufactures, imports, distributes and researches healthcare products including dietary supplements, pharmaceuticals, cosmeceuticals, functional foods, cosmetics, medical equipment and aesthetic innovation products for humans; pet healthcare and livestock products such as vaccines, nutraceuticals, shampoos, ear and teeth cleaners, pee pads and animal feeds; and hospital services encompassing treatment for cardiovascular, bone and joint, kidney, obstetrics, gynecology and other specialized diseases, operating through human healthcare, animal healthcare and hospital/clinics segments primarily in Thailand with manufacturing capabilities for solid, liquid and semi-solid dosage forms. The Bangkok-based company, founded in 2006 and headquartered at 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong Sub-District, Bang Rak District, serves retail customers via distributors and holds investment promotion certificates from the Board of Investment for innovative lines like glaucoma eye-drop production. In November 2025, Inter Pharma agreed to acquire an additional 49% stake in Interpharma-ZEAvita Company Limited from Thai Union Ingredients for full 99.99% ownership using internal funds, subject to board approval and expected to close in Q4 2025.